Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035331.xml
CC BY-NC-ND 4.0 · Revista Urología Colombiana / Colombian Urology Journal 2021; 30(02): 145-152
DOI: 10.1055/s-0041-1731669
DOI: 10.1055/s-0041-1731669
Guidelines
Guía de manejo Hiperplasia Prostática Benigna (SCU 2021)
Benign Prostatic Hyperplasia Guideline (SCU 2021)
1. INTRODUCCIÓN
La Sociedad Colombiana de Urología (SCU) decidió realizar la adaptación de la guía de manejo de HPB.[1] [2] Las recomendaciones finales de esta guía se basan en una revisión sistemática de la literatura hasta 2020. Esta guía ofrece evidencia práctica en la evaluación y el tratamiento de hombres mayores de 40 años que se presentan con síntomas del tracto urinario inferior (SUOB).
Publication History
Article published online:
30 June 2021
© 2021. Sociedad Colombiana de Urología. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
Referencias
- 1 NZGG. Handbook for the Preparation of Explicit Evidence-Based Clinical Practice Guidelines. New Zealand Guidelines Group; 2001: 67-76
- 2 National Institute for Clinical Excellence, (February 2004, updated 2005). Guideline Development Methods: Information for National Collaborating Centers and Guideline Developers. London: National Institute for Clinical Excellence; http://www.nice.org.uk
- 3 Martin SA, Haren MT, Marshall VR, Lange K, Wittert GA. Members of the Florey Adelaide Male Ageing Study. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol 2011; 29 (02) 179-184 https://www.ncbi.nlm.nih.gov/pubmed/20963421
- 4 d'Urologie SI. (SIU), Lower Urinary Tract Symptoms (LUTS): An International Consultation on Male LUTS., C. Chapple & P. Abrams, Editors. 2013 https://www.siuurology.org/themes/web/assets/files/ICUD/pdf/Male%20Lower%20Urinary%20Tract%20Symptoms%20(LUTS).pdf
- 5 Kupelian V, Wei JT, O'Leary MP. et al; BACH Survery Investigators. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 2006; 166 (21) 2381-2387 https://www.ncbi.nlm.nih.gov/pubmed/17130393
- 6 Agarwal A, Eryuzlu LN, Cartwright R. et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol 2014; 65 (06) 1211-1217 https://www.ncbi.nlm.nih.gov/pubmed/24486308
- 7 De Ridder D, Roumeguère T, Kaufman L. Urgency and other lower urinary tract symptoms in men aged ≥ 40 years: a Belgian epidemiological survey using the ICIQ-MLUTS questionnaire. Int J Clin Pract 2015; 69 (03) 358-365 https://www.ncbi.nlm.nih.gov/pubmed/25648652
- 8 Kogan MI, Zachoval R, Ozyurt C, Schäfer T, Christensen N. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin 2014; 30 (10) 2119-2130 https://www.ncbi.nlm.nih.gov/pubmed/24932562
- 9 Chapple CR, Wein AJ, Abrams P. et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol 2008; 54 (03) 563-569 https://www.ncbi.nlm.nih.gov/pubmed/18423969
- 10 Yang DY, Lee WK. A current perspective on post-micturition dribble in males. Investig Clin Urol 2019; 60 (03) 142-147
- 11 Martin S, Lange K, Haren MT, Taylor AW, Wittert G. Members of the Florey Adelaide Male Ageing Study. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. J Urol 2014; 191 (01) 130-137
- 12 Chapple CR, Al-Shukri SH, Gattegno B. et al. Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Efficacy and tolerability in a placebo and active comparator controlled phase 3a study. European Urology Supplements (ISSN 1569-9056) 2005; 4: 33-44
- 13 Karavitakis M, Kyriazis I, Omar MI. et al. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. Eur Urol 2019; 75 (05) 788-798
- 14 Yuan J, Liu Y, Yang Z, Qin X, Yang K, Mao C. The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. Curr Med Res Opin 2013; 29 (03) 279-287
- 15 van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 2006; 66 (03) 287-301 https://www.ncbi.nlm.nih.gov/pubmed/16526818
- 16 Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011; 108 (03) 388-394 https://www.ncbi.nlm.nih.gov/pubmed/21631695
- 17 Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008; 101 (Suppl 3): 17-21 https://www.ncbi.nlm.nih.gov/pubmed/18307681
- 18 Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 2006; 97 (05) 1003-1006 https://www.ncbi.nlm.nih.gov/pubmed/16643482
- 19 Pattanaik S, Mavuduru RS, Panda A. et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane Database Syst Rev 2018; 11: CD010060 https://www.ncbi.nlm.nih.gov/pubmed/30480763
- 20 Buck AC. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 2004; 172 (5 Pt 1): 1792-1799 https://www.ncbi.nlm.nih.gov/pubmed/15540722
- 21 Roehrborn CG, Oyarzabal Perez I, Roos EP. et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int 2015; 116 (03) 450-459 https://www.ncbi.nlm.nih.gov/pubmed/25565364
- 22 Kaplan SA, Lee JY, Meehan AG, Kusek JW. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial. J Urol 2016; 195 (06) 1825-1829 https://www.ncbi.nlm.nih.gov/pubmed/26678956
- 23 Drake MJ, Chapple C, Sokol R. et al; NEPTUNE Study Group. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol 2015; 67 (02) 262-270 https://www.ncbi.nlm.nih.gov/pubmed/25070148
- 24 Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol 2006; 50 (05) 969-979 , discussion 980 https://www.ncbi.nlm.nih.gov/pubmed/16469429
- 25 Riedinger CB, Fantus RJ, Matulewicz RS, Werntz RP, Rodriguez JF, Smith ND. The impact of surgical duration on complications after transurethral resection of the prostate: an analysis of NSQIP data. Prostate Cancer Prostatic Dis 2019; 22 (02) 303-308 https://www.ncbi.nlm.nih.gov/pubmed/30385836
- 26 Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol 2009; 56 (05) 798-809 https://www.ncbi.nlm.nih.gov/pubmed/19595501
- 27 Omar MI, Lam TB, Alexander CE. et al. Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP). BJU Int 2014; 113 (01) 24-35 https://www.ncbi.nlm.nih.gov/pubmed/24053602
- 28 Inzunza G. et al. Bipolar or monopolar transurethral resection for benign prostatic hyperplasia? Reseccion transuretral bipolar o monopolar para hiperplasia prostatica benigna?. 2018; 18: e7134 https://www.ncbi.nlm.nih.gov/pubmed/29351269
- 29 Treharne C. et al. Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review, Meta-analysis, and Cost-Consequence Model. Eur Urol focus. 2016 https://www.ncbi.nlm.nih.gov/pubmed/28753756
- 30 Autorino R, Damiano R, Di Lorenzo G. et al. Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Eur Urol 2009; 55 (04) 922-929 https://www.ncbi.nlm.nih.gov/pubmed/19185975
- 31 Poulakis V, Dahm P, Witzsch U, Sutton AJ, Becht E. Transurethral electrovaporization vs transurethral resection for symptomatic prostatic obstruction: a meta-analysis. BJU Int 2004; 94 (01) 89-95 https://www.ncbi.nlm.nih.gov/pubmed/15217438
- 32 Kaya C, Ilktac A, Gokmen E, Ozturk M, Karaman IM. The long-term results of transurethral vaporization of the prostate using plasmakinetic energy. BJU Int 2007; 99 (04) 845-848 https://www.ncbi.nlm.nih.gov/pubmed/17378844
- 33 Sun J. et al. Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) on patients receiving dual antiplatelet therapy (DAPT). World J Urol 2018; 36: 271 https://www.ncbi.nlm.nih.gov/pubmed/ 29138929
- 34 Briganti A, Naspro R, Gallina A. et al. Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial. J Urol 2006; 175 (05) 1817-1821 https://www.ncbi.nlm.nih.gov/pubmed/16600770
- 35 Thangasamy IA, Chalasani V, Bachmann A, Woo HH. Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012. Eur Urol 2012; 62 (02) 315-323 https://www.ncbi.nlm.nih.gov/pubmed/22575913
- 36 Świniarski PP, Stępień S, Dudzic W, Kęsy S, Blewniewski M, Różański W. Thulium laser enucleation of the prostate (TmLEP) vs. transurethral resection of the prostate (TURP): evaluation of early results. Cent European J Urol 2012; 65 (03) 130-134 https://www.ncbi.nlm.nih.gov/pubmed/24578948
- 37 Becker B, Herrmann TRW, Gross AJ, Netsch C. Thulium vapoenucleation of the prostate versus holmium laser enucleation of the prostate for the treatment of large volume prostates: preliminary 6-month safety and efficacy results of a prospective randomized trial. World J Urol 2018; 36 (10) 1663-1671
- 38 Roehrborn CG, Barkin J, Gange SN. et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017; 24 (03) 8802-8813 https://www.ncbi.nlm.nih.gov/pubmed/28646935
- 39 Sønksen J, Barber NJ, Speakman MJ. et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 2015; 68 (04) 643-652 https://www.ncbi.nlm.nih.gov/pubmed/25937539